EP0888285B1 - Novel bridged cyclic amino acids as pharmaceutical agents - Google Patents
Novel bridged cyclic amino acids as pharmaceutical agents Download PDFInfo
- Publication number
- EP0888285B1 EP0888285B1 EP97906630A EP97906630A EP0888285B1 EP 0888285 B1 EP0888285 B1 EP 0888285B1 EP 97906630 A EP97906630 A EP 97906630A EP 97906630 A EP97906630 A EP 97906630A EP 0888285 B1 EP0888285 B1 EP 0888285B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- integer
- compound according
- pharmaceutical composition
- anyone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C=*C(CC1(C2CCCC1CCC2)C#N)=N Chemical compound C=*C(CC1(C2CCCC1CCC2)C#N)=N 0.000 description 6
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- RBENBGVLYXGADJ-UHFFFAOYSA-N CCOC(CC1(C(CC2)CC2C1)C#N)=N Chemical compound CCOC(CC1(C(CC2)CC2C1)C#N)=N RBENBGVLYXGADJ-UHFFFAOYSA-N 0.000 description 1
- JAXXGSYHXYYGTR-UHFFFAOYSA-N N#CC(C(O)=O)=C1C2CCCC1CCC2 Chemical compound N#CC(C(O)=O)=C1C2CCCC1CCC2 JAXXGSYHXYYGTR-UHFFFAOYSA-N 0.000 description 1
- DQDBFMWENLBGDI-UHFFFAOYSA-N N=CN=C(C=C1)C=CC1=O Chemical compound N=CN=C(C=C1)C=CC1=O DQDBFMWENLBGDI-UHFFFAOYSA-N 0.000 description 1
- LVXXPJDCJUDQAB-UHFFFAOYSA-N O=C(C1)NCC11C2CCCC1CCC2 Chemical compound O=C(C1)NCC11C2CCCC1CCC2 LVXXPJDCJUDQAB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms
Definitions
- R 1 is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in United States Patent Number 4,024,175 and its divisional United States Patent Number 4,087,544.
- the uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions.
- the compounds are useful in geriatric patients.
- the novel bridged cyclic amino acids, their derivatives, pharmaceutically acceptable salts, and prodrugs are useful in a variety of disorders.
- the disorders include: epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders.
- the compounds are those of formula a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is a bridged ring selected from wherein
- Preferred compounds are those of Formula I wherein or a pharmaceutically acceptable-salt thereof wherein A is a bridged ring selected from wherein
- Novel intermediates useful in the preparation of the final products are disclosed as well as a novel process for the preparation of the compounds.
- alkyl is a straight or branched group of from 1 to 6 carbon atoms including but not limited to methyl, ethyl, propyl, n-propyl, isopropyl, butyl, 2-butyl, tert-butyl, pentyl, hexyl, and n-hexyl.
- the benzyl and phenyl groups may be unsubstituted or-substituted by from 1 to 3 substituents selected from halogen, CF 3 , nitro, alkyl, alkoxy.
- amino acids are amphoteric
- pharmacologically compatible salts when R is hydrogen can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulphuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, and ascorbic.
- salts with alkali metals or alkaline earit metals, for example, sodium, potassium, magnesium, or calcium are formed.
- Salts with quaternary ammonium ions can also be prepared with, for example, the tetramethyl-ammonium ion.
- the carboxyl group of the amino acids can be esterified by known means.
- Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.
- the solvated forms, including hydrated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
- each center may exist in the R(D) or S(L) configuration.
- the present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. In all cases where there is a chiral center at the point where the amino methyl and acetic acid moieties are joined to the ring, the center may have either the R or S configuration.
- the compounds of the invention may be synthesized, for example, by utilizing the general strategy (Scheme 1 below) outlined by Griffiths G., et al., Helv. Chim. Acta, 74:309 (1991). Alternatively, they may also be made as shown (in Scheme 2 below), analogously to the published procedure for the synthesis of 3-oxo-2,8-diazaspiro[4,5]decane-8-carboxylic acid tert-butyl ester (1) (Smith P.W., et al., J. Med. Chem. , 38:3772 (1995)). The compounds may also be synthesized by the methods outlined by Satzinger G., et al., (US 4,024,175, and US 4,152,326) (Schemes 3 and 4 below).
- the compounds may be synthesized by utilizing the general strategy exemplified by the synthesis of compounds of formula (1) outlined by G. Griffiths, et al., ( Helv. Chim. Acta , 74;309 (1991)). See Scheme 1 below.
- the compounds of the invention may be made as shown in Scheme 2 below, analogously to the published procedure for the synthesis of 3-oxo-2,8-diazaspiro[4,5]decane-8-carboxylic acid tert-butyl ester (6) (P. W. Smith, et al., J. Med. Chem., 38;3772 (1995)).
- the compounds may also be synthesized by the methods outlined by G. Satzinger, et al., (United States Patent 4,024,175, and Unites States Patent 4,152,326). See Schemes 3 and 4 below.
- pro-drugs examples are:
- Table 1 above shows the binding affinity of the examples to the ⁇ 2 ⁇ subunit.
- Gabapentin (Neurontin®) is about 0.10 to 0.12 ⁇ M in this assay.
- the compounds of the instant invention are expected, therefore, to exhibit pharmacologic properties comparable to gabapentin. For example, as agents for convulsions, anxiety, and pain.
- Neurontin® a marketed drug effective in the treatment of epilepsy.
- Neurontin® is 1-(aminomethyl)-cyclohexaneacetic acid of structural formula
- the compounds of the invention are also expected to be useful in the treatment of epilepsy. See Table 1 above for IC 50 data as compared to Neurontin®.
- the present invention also relates to the use of the compounds for the preparation of pharmaceutical compositions for the treatment of neurodegenerative disorders.
- Such neurodegenerative disorders are, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.
- the above use also covers treating neurodegenerative disorders termed acute brain injury. These include but are not limited to: stroke, head trauma, and asphyxia.
- Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke. Stroke includes both focal and global ischemia. Also, included are transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia such as in a patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like.
- CVA cerebral vascular incident
- Stroke includes both focal and global ischemia.
- transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia such as in a patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like.
- compositions would be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.
- a skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as suffering from stroke for administration by methods of the present invention.
- the compounds of the invention are also expected to be useful in the treatment of depression.
- Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a mechanistic cause for at least some forms of depression.
- the diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt.
- the standards for diagnosis of depression as well as all psychiatric diagnoses are collected in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) referred to as the DSM-IV-R manual published by the American Psychiatric Association, 1994.
- GABA is an inhibitory neurotransmitter with the central nervous system. Within the general context of inhibition, it seems likely that GABA-mimetics might decrease or inhibit cerebral function and might therefore slow function and decrease mood leading to depression.
- the compounds of the instant invention may produce an anticonvulsant effect through the increase of newly created GABA at the synaptic junction. If gabapentin does indeed increase GABA levels or the effectiveness of GABA at the synaptic junction, then it could be classified as a GABA-mimetic and might decrease or inhibit cerebral function and might, therefore, slow function and decrease mood leading to depression.
- GABA agonist or GABA-mimetic might work just the opposite way by increasing mood and thus, be an antidepressant, is a new concept, different from the prevailing opinion of GABA activity heretofore.
- the compounds of the instant invention are also expected to be useful in the treatment of anxiety and of panic as demonstrated by means of standard pharmacological procedures.
- Nociceptive pressure thresholds were measured in the rat paw pressure test using an analgesymeter (Randall-Selitto Method: Randall L.O., Sellitto J.J., A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn., 4 :409-419 (1957)). Male Sprague Dawley rats (70-90 g) were trained on this apparatus before the test day. Pressure was gradually applied to the hind paw of each rat and nociceptive thresholds were determined as the pressure (g) required to elicit paw withdrawal. A cutoff point of 250 g was used to prevent any tissue to the paw.
- Tonic seizures in mice are induced by subcutaneous administration of semicarbazide (750 mg/kg). The latency to the tonic extension of forepaws is noted. Any mice not convulsing within 2.0 hours after semicarbazide are considered protected and given a maximum latency score of 120 minutes.
- mice Male Hooded Lister rats (200-250 g) are obtained from Interfauna (Huntingdon, UK) and male TO mice (20-25 g) are obtained from Bantin and Kingman (Hull, UK). Both rodent species are housed in groups of six. Ten Common Marmosets (Callithrix Jacchus) weighing between 280 and 360 g, bred at Manchester University Medical School (Manchester, UK) are housed in pairs. All animals are housed under a 12-hour light/dark cycle (lights on at 07.00 hour) and with food and water ad libitum.
- IP intraperitoneally
- SC subcutaneously
- the apparatus is an open-topped box, 45 cm long, 27 cm wide, and 27 cm high, divided into a small (2/5) and a large (3/5) area by a partition that extended 20 cm above the walls (Costall B., et al., Exploration of mice in a black and white box: validation as a model of anxiety. Pharmacol. Biochem. Behav., 32:777-785 (1989)).
- the total number of body postures exhibited by the animal towards the threat stimulus (a human standing approximately 0.5 m away from the marmoset cage and staring into the eyes of the marmoset) is recorded during the 2-minute test period.
- the body postures scored are slit stares, tail postures, scent marking of the cage/perches, piloerection, retreats, and arching of the back.
- Each animal is exposed to the threat stimulus twice on the test day before and after drug treatment.
- the difference between the two scores is analyzed using one-way analysis of variance followed by Dunnett's t-test. All drug treatments are carried out SC at least 2 hours after the first (control) threat.
- the pretreatment time for each compound is 40 minutes.
- Rats are trained to press levers for food reward in operant chambers.
- the schedule consists of alternations of four 4-minute unpunished periods on variable interval of 30 seconds signalled by chamber lights on and three 3-minute punished periods on fixed ratio 5 (by footshock concomitant to food delivery) signalled by chamber lights off.
- the degree of footshock is adjusted for each rat to obtain approximately 80% to 90% suppression of responding in comparison with unpunished responding.
- Rats receive saline vehicle on training days.
- the compounds of the instant invention are also expected to be useful in the treatment of pain and phobic disorders ( Am. J. Pain Manag. , 5:7-9 (1995)).
- the compounds of the instant invention are also expected to be useful in treating the symptoms of manic, acute or chronic, single upside, or recurring. They are also expected to be useful in treating and/or preventing bipolar disorder (United States Patent Application Number 08/440,570 filed May 15, 1995).
- the compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms.
- the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intra-cutaneously, subcutaneously, intraduodenally, or intraperitoneally.
- the compounds of the present invention can be administered by inhalation, for example, intranasally.
- the compounds of the present invention can be administered transdermally.
- the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component.
- the drug may be administered three times daily as, for example, capsules of 100 or 300 mg.
- the composition can, if desired, also contain other compatible therapeutic agents.
- the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily.
- a daily dose range of about 0.01 mg to about 100 mg/kg is preferred.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
- the binitrile (10 mmol) was dissolved in a mixture of ethanol (50 mL) and toluene (20 mL) and cooled to 0°C in an ice bath. The mixture was then saturated with HCl gas. The flask was stoppered and the mixture left to stand at room temperature. After 60 hours, the solvent was removed in vacuo. The residue was triturated with diethyl ether to give 1.97 g (70%) of a white powder, mp 190-210°C.
- the imidate (6.7 mmol) was dissolved in water (100 mL) and the pH adjusted to pH 1.5 by addition of 1N HCl. The resulting solution was stirred at room temperature overnight. The solution was then shaken with ethyl acetate (100 mL). The organic phase was separated, washed with water, dried (MgSO 4 ), and the solvent removed in vacuo to give 1.41 g (90%) of a clear oil which crystallized on standing, mp 52-56°C.
- Raney nickel catalytic was washed with water (3 ⁇ 30 mL) followed by ethanol (2 ⁇ 30 mL) and added to a solution of the ester (4.5 mmol) in ethanol (40 mL) presaturated with ammonia gas and absolute ethanol (60 mL). The resulting mixture was shaken under an atmosphere of hydrogen gas (50 psi) at 50°C in a Parr apparatus. After 20 hours, the mixture was filtered through Celite and the filtrate evaporated to dryness in vacuo to give 0.811 g (93%) of a white powder, mp 154-157°C.
- IR (Film) ⁇ max cm -1 2971, 2910, 2879, 2224, 1727, 1621, 1449, 1407, 1368, 1326, 1307, 1289, 1271, 1259, 1231, 1207, 1163, 1137, 1105, 1070, 1028, 964, 921, 857, 775, 747.
- the ester (3 mmol) was hydrogenated as in the General method Step 5 at 30°C, 50 psi for 4 hours.
- the solution was passed through a pad of Celite, followed by a pad of silica, washing with ethyl acetate.
- the filtrate was decolourized with charcoal and passed through a second pad of silica.
- the solvent was removed to give a white solid; yield 67%; mp 100-108°C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9730235T SI0888285T1 (en) | 1996-03-14 | 1997-02-18 | Novel bridged cyclic amino acids as pharmaceutical agents |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1343396P | 1996-03-14 | 1996-03-14 | |
US1343P | 1996-03-14 | ||
PCT/US1997/002401 WO1997033859A1 (en) | 1996-03-14 | 1997-02-18 | Novel bridged cyclic amino acids as pharmaceutical agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0888285A1 EP0888285A1 (en) | 1999-01-07 |
EP0888285B1 true EP0888285B1 (en) | 2001-12-12 |
Family
ID=21759944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97906630A Expired - Lifetime EP0888285B1 (en) | 1996-03-14 | 1997-02-18 | Novel bridged cyclic amino acids as pharmaceutical agents |
Country Status (18)
Country | Link |
---|---|
US (1) | US6020370A (ja) |
EP (1) | EP0888285B1 (ja) |
JP (1) | JP2000506862A (ja) |
KR (1) | KR100487032B1 (ja) |
AT (1) | ATE210629T1 (ja) |
AU (1) | AU731279B2 (ja) |
BR (1) | BR9708180A (ja) |
CZ (1) | CZ287598A3 (ja) |
DE (1) | DE69709070T2 (ja) |
EA (1) | EA001214B1 (ja) |
ES (1) | ES2169848T3 (ja) |
IL (1) | IL125364A0 (ja) |
NO (1) | NO984204D0 (ja) |
NZ (1) | NZ331142A (ja) |
PL (1) | PL185990B1 (ja) |
SK (1) | SK282848B6 (ja) |
WO (1) | WO1997033859A1 (ja) |
ZA (1) | ZA972199B (ja) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0934061T1 (en) | 1996-07-24 | 2003-10-31 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
PT1015415E (pt) | 1997-09-18 | 2003-09-30 | Warner Lambert Co | Novos processos estereosselectivos para a preparacao de analogos de gabapentina |
US6984659B2 (en) | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
DE19751062A1 (de) * | 1997-11-18 | 1999-07-08 | Univ Ludwigs Albert | An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels |
CN1495160A (zh) * | 1997-12-16 | 2004-05-12 | ��ʲ | 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
KR20010043831A (ko) | 1998-05-26 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물 |
DK1093366T3 (da) * | 1998-07-09 | 2004-12-06 | Warner Lambert Co | Farmaceutisk sammensætning indeholdende GABA-analoge og et antivirusmiddel til behandling af helvedesild |
CA2378918C (en) | 1999-07-22 | 2007-01-23 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
EP1267896A1 (en) * | 2000-03-28 | 2003-01-02 | Robert J. Delorenzo | Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
NZ522480A (en) * | 2000-06-26 | 2005-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
US6992076B2 (en) | 2000-10-06 | 2006-01-31 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
EP1361847A2 (en) * | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
NZ528151A (en) | 2001-04-19 | 2005-04-29 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
GB2374595A (en) * | 2001-04-19 | 2002-10-23 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
HUP0400183A2 (hu) * | 2001-06-11 | 2004-07-28 | Xenoport Inc. | Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái |
US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
AU2003222033A1 (en) | 2002-03-20 | 2003-10-08 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
US20050153928A1 (en) * | 2002-05-07 | 2005-07-14 | Holick Michael F. | Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
AU2003297927A1 (en) | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
RU2331438C2 (ru) | 2002-12-13 | 2008-08-20 | Уорнер-Ламберт Компани Ллс | Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
MXPA05010515A (es) * | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
JP2007505149A (ja) | 2003-09-11 | 2007-03-08 | ゼノポート,インコーポレイティド | ギャバ類似体のプロドラッグを用いる尿失禁の治療および/あるいは予防 |
EP1663398B1 (en) | 2003-09-12 | 2009-11-25 | Pfizer Limited | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
NZ545989A (en) | 2003-09-17 | 2009-10-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
MXPA06004088A (es) * | 2003-10-14 | 2006-06-27 | Xenoport Inc | Forma cristalina de un analogo del acido gamma-aminobutirico. |
DK1691811T3 (da) | 2003-12-11 | 2014-10-20 | Sunovion Pharmaceuticals Inc | Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression |
RU2440112C2 (ru) | 2004-11-04 | 2012-01-20 | Ксенопорт, Инк. | Пероральная дозированная форма габапентина замедленного высвобождения |
WO2007070801A2 (en) * | 2005-12-12 | 2007-06-21 | Allaccem, Inc. | Methods and systems for preparing antimicrobial films and coatings |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
CN101652133A (zh) * | 2006-12-08 | 2010-02-17 | 克塞诺波特公司 | Gaba类似物的前药用于治疗疾病的用途 |
CN101600458A (zh) | 2006-12-22 | 2009-12-09 | 瑞蔻达蒂爱尔兰有限公司 | 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗 |
DK2125026T3 (en) * | 2007-02-21 | 2014-12-08 | Allaccem Inc | FORMATIONS BASED ON bridged POLYCYCLIC COMPOUNDS FOR INHIBITION AND RELIEF OF DISEASES |
WO2008157408A2 (en) * | 2007-06-15 | 2008-12-24 | Xenoport, Inc. | Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
US8188068B2 (en) * | 2007-08-10 | 2012-05-29 | Allaccem, Inc. | Bridged polycyclic compound based compositions for coating oral surfaces in pets |
US8153618B2 (en) * | 2007-08-10 | 2012-04-10 | Allaccem, Inc. | Bridged polycyclic compound based compositions for topical applications for pets |
US8153617B2 (en) * | 2007-08-10 | 2012-04-10 | Allaccem, Inc. | Bridged polycyclic compound based compositions for coating oral surfaces in humans |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2009061934A1 (en) * | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
US7872046B2 (en) * | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
JP5563483B2 (ja) * | 2008-01-25 | 2014-07-30 | ゼノポート,インコーポレイティド | アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解 |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
JP5476305B2 (ja) * | 2008-08-07 | 2014-04-23 | 杏林製薬株式会社 | ビシクロ[2.2.2]オクチルアミン誘導体の製造方法 |
BRPI0919811B1 (pt) | 2008-10-08 | 2022-04-19 | Xgene Pharmaceutical Inc | Conjugados de gaba e métodos de uso dos mesmos |
WO2010084798A1 (ja) * | 2009-01-21 | 2010-07-29 | 第一三共株式会社 | 3環性化合物 |
US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
US10130715B2 (en) | 2013-01-28 | 2018-11-20 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor |
EP4227293A3 (en) | 2018-05-14 | 2023-10-04 | Xgene Pharmaceutical Inc | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743742A (en) * | 1969-06-17 | 1973-07-03 | Merck & Co Inc | Producing anti-fibrinolytic activity with aminobicycloacetic acid derivatives |
US3641129A (en) * | 1969-06-17 | 1972-02-08 | Merck & Co Inc | Antifibrinolytic compounds |
YU36150B (en) * | 1974-11-22 | 1982-02-25 | Pliva Zagreb | Process for preparing alpha-amino-1-adamantyl acetic acid |
US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2543821C2 (de) * | 1974-12-21 | 1984-10-18 | Gödecke AG, 1000 Berlin | Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
-
1997
- 1997-02-18 CZ CZ982875A patent/CZ287598A3/cs unknown
- 1997-02-18 EA EA199800797A patent/EA001214B1/ru unknown
- 1997-02-18 SK SK1248-98A patent/SK282848B6/sk unknown
- 1997-02-18 JP JP9532604A patent/JP2000506862A/ja not_active Ceased
- 1997-02-18 WO PCT/US1997/002401 patent/WO1997033859A1/en not_active Application Discontinuation
- 1997-02-18 ES ES97906630T patent/ES2169848T3/es not_active Expired - Lifetime
- 1997-02-18 PL PL97328800A patent/PL185990B1/pl not_active IP Right Cessation
- 1997-02-18 KR KR10-1998-0707228A patent/KR100487032B1/ko not_active IP Right Cessation
- 1997-02-18 IL IL12536497A patent/IL125364A0/xx not_active IP Right Cessation
- 1997-02-18 AT AT97906630T patent/ATE210629T1/de not_active IP Right Cessation
- 1997-02-18 AU AU21271/97A patent/AU731279B2/en not_active Ceased
- 1997-02-18 NZ NZ331142A patent/NZ331142A/en unknown
- 1997-02-18 US US09/068,861 patent/US6020370A/en not_active Expired - Fee Related
- 1997-02-18 EP EP97906630A patent/EP0888285B1/en not_active Expired - Lifetime
- 1997-02-18 DE DE69709070T patent/DE69709070T2/de not_active Expired - Fee Related
- 1997-02-18 BR BR9708180A patent/BR9708180A/pt not_active IP Right Cessation
- 1997-03-13 ZA ZA9702199A patent/ZA972199B/xx unknown
-
1998
- 1998-09-11 NO NO984204A patent/NO984204D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO984204L (no) | 1998-09-11 |
PL185990B1 (pl) | 2003-09-30 |
NO984204D0 (no) | 1998-09-11 |
DE69709070D1 (de) | 2002-01-24 |
CZ287598A3 (cs) | 1999-02-17 |
SK124898A3 (en) | 1999-02-11 |
KR19990087755A (ko) | 1999-12-27 |
IL125364A0 (en) | 1999-03-12 |
WO1997033859A1 (en) | 1997-09-18 |
ZA972199B (en) | 1997-09-17 |
NZ331142A (en) | 2001-04-27 |
AU731279B2 (en) | 2001-03-29 |
EA199800797A1 (ru) | 1999-04-29 |
EP0888285A1 (en) | 1999-01-07 |
DE69709070T2 (de) | 2002-06-20 |
US6020370A (en) | 2000-02-01 |
BR9708180A (pt) | 1999-07-27 |
JP2000506862A (ja) | 2000-06-06 |
ES2169848T3 (es) | 2002-07-16 |
AU2127197A (en) | 1997-10-01 |
EA001214B1 (ru) | 2000-12-25 |
KR100487032B1 (ko) | 2005-12-21 |
SK282848B6 (sk) | 2002-12-03 |
PL328800A1 (en) | 1999-02-15 |
ATE210629T1 (de) | 2001-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0888285B1 (en) | Novel bridged cyclic amino acids as pharmaceutical agents | |
EP0888286B1 (en) | Novel substituted cyclic amino acids as pharmaceutical agents | |
EP0888325B1 (en) | Novel cyclic amino acids as pharmaceutical agents | |
AU757445B2 (en) | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel | |
US6635673B1 (en) | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | |
CA2245647C (en) | Novel bridged cyclic amino acids as pharmaceutical agents | |
US20050250800A1 (en) | Conformationally constrained compounds as pharmaceutical agents | |
PT888285E (pt) | Novos amino acidos ciclicos em ponte como agentes farmaceuticos | |
MXPA00009494A (en) | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980814 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 980814;LT PAYMENT 980814;LV PAYMENT 980814;RO PAYMENT 980814;SI PAYMENT 980814 |
|
17Q | First examination report despatched |
Effective date: 19991108 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 19980814;LT PAYMENT 19980814;LV PAYMENT 19980814;RO PAYMENT 19980814;SI PAYMENT 19980814 |
|
REF | Corresponds to: |
Ref document number: 210629 Country of ref document: AT Date of ref document: 20011215 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69709070 Country of ref document: DE Date of ref document: 20020124 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20011217 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2169848 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20020400932 Country of ref document: GR |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: SI Ref legal event code: IF |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060228 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20061215 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20070103 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20070105 Year of fee payment: 11 Ref country code: AT Payment date: 20070105 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20070108 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20070109 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20070110 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20070111 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20070115 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20070205 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20070207 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20070221 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20070228 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20070302 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20070123 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20070201 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20080818 |
|
BERE | Be: lapsed |
Owner name: *WARNER-LAMBERT CY Effective date: 20080228 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20080218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080818 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080228 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080229 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080218 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080229 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20080901 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080901 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080218 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20081031 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20081112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080219 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080218 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080229 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080229 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20080219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080903 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080218 |